Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Insulin Lispro
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Lupin Ltd
Deal Size : Undisclosed
Deal Type : Acquisition
Lupin Acquires Huminsulin from Lilly, Enhance Diabetes Portfolio
Details : Through the acquisition, Lupin will enhance its portfolio and gain the right to commercialize Humulin N (human insulin) in India. It is indicated for the treatment of diabetes mellitus.
Product Name : Humulin N
Product Type : Peptide
Upfront Cash : Undisclosed
December 30, 2024
Lead Product(s) : Insulin Lispro
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Lupin Ltd
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Insulin Lispro
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Lilly, EVA Pharma Announce Regulatory Approval for Locally Manufactured Insulin
Details : Humalog (insulin) is a peptide based drug, works by showing agonistic action for GLP-1R, mainly indicated for the treatment of patients with type 1 and 2 diabetes.
Product Name : Humalog
Product Type : Peptide
Upfront Cash : Inapplicable
December 17, 2024
Lead Product(s) : Insulin Lispro
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Insulin Lispro
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Eli Lilly
Deal Size : $344.2 million
Deal Type : Acquisition
Lilly Completes Acquisition of Sigilon Therapeutics
Details : Through the acquisition, Lilly gains control of the partnered encapsulated cell therapies, including SIG-002 (human insulin), for the treatment of type 1 diabetes.
Product Name : SIG-002
Product Type : Peptide
Upfront Cash : $344.2 million
August 14, 2023
Lead Product(s) : Insulin Lispro
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Eli Lilly
Deal Size : $344.2 million
Deal Type : Acquisition
Lead Product(s) : Insulin Lispro
Therapeutic Area : Endocrinology
Study Phase : Undisclosed
Sponsor : Eli Lilly
Deal Size : $344.2 million
Deal Type : Acquisition
Lilly to Acquire Sigilon Therapeutics
Details : Through the acquisition, Lilly will gain control of the partnered encapsulated cell therapies, including SIG-002 (human insulin), for the treatment of type 1 diabetes.
Product Name : SIG-002
Product Type : Peptide
Upfront Cash : $344.2 million
June 29, 2023
Lead Product(s) : Insulin Lispro
Therapeutic Area : Endocrinology
Highest Development Status : Undisclosed
Sponsor : Eli Lilly
Deal Size : $344.2 million
Deal Type : Acquisition
Lead Product(s) : Insulin Lispro
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Biocon
Deal Size : Inapplicable
Deal Type : Inapplicable
Biocon Biologics’ Partner Receives Approval for Human Insulin for IV Infusion
Details : Inpremzia is an approved medicine used to treat people with diabetes who need insulin to keep their blood glucose (sugar) level controlled. It contains the active substance insulin human.
Product Name : Inpremzia
Product Type : Peptide
Upfront Cash : Inapplicable
April 25, 2022
Lead Product(s) : Insulin Lispro
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Biocon
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Insulin Lispro
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Adocia
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The primary objective of Phase 3 program is to demonstrate non-inferiority of BC Lispro on HbA1c reduction from baseline vs. Humalog. BioChaperone® Lispro (BC Lispro) is ultra-rapid prandial insulin containing insulin lispro and Adocia’s proprietary t...
Product Name : BioChaperone Lispro
Product Type : Peptide
Upfront Cash : Inapplicable
October 14, 2021
Lead Product(s) : Insulin Lispro
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Adocia
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Insulin Lispro
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Adocia Initiates Phase 2 Clinical Trial for M1Pram in Patients with Type 1 Diabetes
Details : The purpose of the study is to confirm and optimize the safety and efficacy of M1Pram in comparison with insulin lispro (Humalog®, Eli Lilly) in regard to glycemic control and body weight reduction.
Product Name : BC LisPram
Product Type : Peptide
Upfront Cash : Inapplicable
October 03, 2021
Lead Product(s) : Insulin Lispro
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Insulin Lispro,Pramlintide
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Adocia Initiates BC LisPram Phase 1 Clinical Trial in Pump for People with Type 1 Diabetes
Details : Pramlintide, despite being the only drug approved as an adjunct to insulin in type 1 diabetes, is underused as it requires three additional daily injections in addition to the multiple injections of insulin.
Product Name : BC LisPram
Product Type : Peptide
Upfront Cash : Inapplicable
June 29, 2021
Lead Product(s) : Insulin Lispro,Pramlintide
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Insulin Lispro
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Eli Lilly
Deal Size : Undisclosed
Deal Type : Partnership
Cipla to sell Eli Lilly's Insulin Products Humalog, Trulicity in India
Details : As a part of this agreement, Lilly will transfer its rights in India to sell, promote and distribute the aforesaid two Lilly Diabetes products – Humalog® & TrulicityTM to Cipla, subject to all regulatory approvals.
Product Name : Humalog
Product Type : Peptide
Upfront Cash : Undisclosed
April 10, 2021
Lead Product(s) : Insulin Lispro
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Eli Lilly
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Insulin Lispro
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Eli Lilly
Deal Size : Undisclosed
Deal Type : Partnership
Lilly and Dexcom Team Up on New Program to Help Improve Diabetes Management
Details : Companies will partner to promote Lyumjev, Lilly's new rapid-acting insulin, with Dexcom G6 Continuous Glucose Monitoring (CGM), highlighting the benefits of using each.
Product Name : Lyumjev
Product Type : Peptide
Upfront Cash : Undisclosed
July 10, 2020
Lead Product(s) : Insulin Lispro
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Eli Lilly
Deal Size : Undisclosed
Deal Type : Partnership